RIGI and non-small cell lung carcinoma: For instance, the tumor-suppressive circRNA circNDUFB2, which activates the RIG-I–MAVS innate immune pathway, has been correlated with enhanced interferon signaling and immune cell infiltration in NSCLC, implying that its expression could predict favorable responses to immunotherapy (119).